Daniel Gehrlach
2 presentations
-
BH-200 (NELIVAPTAN), A VASOPRESSIN V1B RECEPTOR ANTAGONIST, IN GENETICALLY DEFINED SUBGROUPS OF MDD: PRECISION TARGETING OF HPA-AXIS DYSREGULATION IN THE OLIVE PHASE 2 PROGRAM
-
T25. BH-200 (NELIVAPTAN), A VASOPRESSIN V1B RECEPTOR ANTAGONIST, IN GENETICALLY DEFINED SUBGROUPS OF MDD: PRECISION TARGETING OF HPA-AXIS DYSREGULATION IN THE OLIVE PHASE 2 PROGRAM